NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT
- 199
· PRESS RELEASE · PRESS RELEASE · PRESS RELEASE
NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF
OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE
TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT
Paris and Boston, July 9, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has today announced having received a first payment within the grant awarded by the National Agency for Research (ANR) representing a total amount up to €702.000 , for its preclinical development program AllergyVacs, conducted in collaboration with Inserm and the Immunology and Allergy Department of Pasteur Institute1.
Neovacs’ proof of concept in allergies with its new IL-4 / IL-13 Kinoid therapeutic vaccine was recently presented at two major scientific congresses (Antibodies and Complement 2019 & EAACI2 2019), with a strong interest manifested by the scientific and medical community. The study demonstrated in a representative allergic asthma model that a treatment with IL-4 / IL-13 Kinoid enhanced the production of polyclonal antibodies, which neutralize the two targeted cytokines IL-4 and IL-13, both being development factors for allergic asthma, thus avoiding the occurrance of symptoms.
The submission of this preclinical results to be published in a scientific publication is actually ongoing.
About Neovacs
Listed on Euronext Growth since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company’s proprietary technology for inducing a polyclonal immune response (covered by four patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts
| NEOVACS Corporate Communication & Investor Relations Charlène Masson +33 1 53 10 93 00 [email protected] | NEWCAP – Media Annie-Florence Loyer Tél : +33 (0)6 88 20 35 59 / +33 (0)1 44 71 00 12 [email protected] Léa Jacquin Tel : +33(0)1 44 71 20 41 [email protected] | ORPHEON FINANCE Financial Communication and Investor Relations James Palmer +33 7 60 92 77 74 [email protected] |
1 Cf. Press Release published January 8 , 2019 https://bit.ly/2Jo65TO
2 European Academy of Allergy and Clinical Immunology Annual Congress
Attachment
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases, financial disclosures and multimedia content to media, investors, and consumers worldwide.
